Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to include MET IHC testing using ...

The National Health Insurance Administration (NHIA) is to expand National Health Insurance (NHI) coverage to include two ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

Title : Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated ...

Specifically, Elahere (mirvetuximab soravtansine) can be used in adults with platinum-resistant, FRα-expressing high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer ...

The study enrolled adults with platinum-resistant, FRα-expressing high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic ...

IMUNON’s Phase 2 OVATION 2 trial of IMNN-001 in advanced ovarian cancer showed a 13-month OS increase (46 vs. 33 months) and ...

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatelli ...

DelveInsight’s, “Peritoneal Cancer Pipeline Insight 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Peritoneal Cancer pipeline landscape.

Using data from the Global Burden of Disease 2021 database, researchers identified specific etiologies and other factors contributing to the burden of primary liver cancer in patients across the ...